Literature DB >> 28815836

[2.2]Paracyclophanes with N-Heterocycles as Ligands for Mono- and Dinuclear Ruthenium(II) Complexes.

Carolin Braun1, Martin Nieger2, Werner R Thiel3, Stefan Bräse1,4.   

Abstract

[2.2]Paracyclophane, with its unique structure, allows the design of unusual 3D structures by functionalization of this rigid and stable hydrocarbon scaffold. Therefore different mono- and homodisubstituted [2.2]paracyclophanes with pyridyl, pyrimidyl and oxazolinyl substituents were developed in order to evaluate their ability as bridging ligands for two ruthenium centres. With the successfully synthesized [2.2]paracyclophane-based N-donor functions, the cycloruthenation reaction using [RuCl2 (p-cymene)]2 as precursor was explored. Compared to 2-phenylpyridine, the [2.2]paracyclophane derivative is clearly inferior in the cycloruthenation reaction, resulting in poor yields for the neutral complexes. By addition of KPF6 , the cationic complexes can be obtained in good yields and are formed diastereoselectively in case of a pyridyl substituent, resulting in only one diastereomer for dinuclear ruthenium complexes of bispyridyl-substituted [2.2]paracyclophanes as bridging ligands.
© 2017 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  chirality; cyclophanes; diastereoselectivity; metallacycle; ruthenium

Year:  2017        PMID: 28815836     DOI: 10.1002/chem.201703291

Source DB:  PubMed          Journal:  Chemistry        ISSN: 0947-6539            Impact factor:   5.236


  2 in total

1.  New Paracyclophanylthiazoles with Anti-Leukemia Activity: Design, Synthesis, Molecular Docking, and Mechanistic Studies.

Authors:  Ashraf A Aly; Stefan Bräse; Alaa A Hassan; Nasr K Mohamed; Lamiaa E Abd El-Haleem; Martin Nieger; Nesrin M Morsy; Elshimaa M N Abdelhafez
Journal:  Molecules       Date:  2020-07-07       Impact factor: 4.411

2.  The concise synthesis and resolution of planar chiral [2.2]paracyclophane oxazolines by C-H activation.

Authors:  Shashank Tewari; Maulik N Mungalpara; Suraj Patel; Gareth J Rowlands
Journal:  RSC Adv       Date:  2022-03-17       Impact factor: 3.361

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.